What is LOPJLB’s current signal on CHRS?

LOPJLB’s latest quantitative signal on Coherus Oncology, Inc. (CHRS) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is CHRS in?

Coherus Oncology, Inc. (CHRS) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Coherus Oncology, Inc. (CHRS) do?

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed …

Where is Coherus Oncology, Inc. based / listed?

Coherus Oncology, Inc. is based in US, listed on NASDAQ.

Coherus Oncology, Inc. (CHRS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$1.07+0.00%Close

SELLCRISIS · day 12

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $131M
Beta: 0.99
P/E (TTM): -1.01

Short % float: 20.13%
Days to cover: 12.5
SI change: +2.1%

1W: -7.76%
1M: -20.15%

vs SPY 1W: -8.92%
vs SPY 1M: -23.14%

Industry peers

FMP comparable companies · ranked by market cap

SLSSELLSELLAS Life Sciences Group, Inc.$2.2BBEARQ -9$11.65+3.46%
AVTXSELLAvalo Therapeutics, Inc.$718MCRISISQ -10$13.65+1.64%
OABIBUYOmniAb, Inc.$694MBEARQ -11$4.79+2.79%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Key stats

Industry peers

Prediction markets

Company news